25 results
8-K
EX-10.1
NVTAQ
Invitae Corp
5 Jul 23
Departure of Directors or Certain Officers
4:53pm
that conflicts with this Agreement or otherwise creates a conflict of interest with Consultant’s Services.
10.Term; Termination. This Agreement is effective
PRE 14A
NVTAQ
Invitae Corp
4 Apr 22
Preliminary proxy
4:15pm
for potential conflict of interest situations on an ongoing basis and all such transactions relating to executive officers and directors must be approved by our
8-K
EX-10.1
ju1qkr3slonc43
5 Apr 21
Invitae Announces $1.15 Billion Investment Supporting Ongoing Growth Initiatives
4:13pm
8-K
EX-10.2
wyaukvb4tbi33lui6
5 Oct 20
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
4:17pm
8-K
EX-10.3
drq4935 7kst
5 Oct 20
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
4:17pm
425
o7ela8
24 Jun 20
Business combination disclosure
5:11pm
8-K
EX-2.1
pwsyhar6c6nhu
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-10.1
w3f9hk95x wvfzwzy
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-10.3
2s1pe
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-10.2
p20m4m
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-10.2
ts6vid0fu75 rcu
7 Nov 18
Invitae Reports 106% Annual Revenue Growth Driven by 95% Annual Growth in Volume
4:14pm
10-K
kpn65
30 Mar 15
Annual report
12:00am